How to Deliver Safe and Effective Adoptive Cell Therapy Products to Clinical Promise, Commercial Scale Manufacturing and Patients

The event brings together leaders from cancer research institutes, patient advocacy groups, early and late-stage investors, pharmas, & biotechs. 300+, 20+ company presentations, 50+% attendees are corporate and financial investors, analysts, bankers and advisors.

NCI and CDMRP are awarding over $7 BILLION in funding for cancer R&D. To learn more, listen to our free webinar about these opportunities.

Find out about more than $7 Billion In Funding Opportunities for Cancer Research – and our webinar all about them

In fiscal year 2022 the Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) will provide funds for research into cancers…

Dr. Donna Kimbark discusses CDMRP’s unique non-dilutive funding opportunities for cancer R&D.


NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle, from basic research, through pre-clinical activities and early phase clinical trials.

In this webinar, we discuss key cancer related opportunities, focusing on the new set of solicitations from the National Cancer Institute (NCI) and the soon to be released CDMRPs (DoD) that are available for life science organizations.


View Slide Deck